Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Rudnicki

Showing results (11-20 of 93) with videos related to

Pageof 10
Sort By:
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|July 26, 2015
RNA expression signatures and posttranscriptional regulation in diabetic nephropathyMichael Rudnicki, Anneleen Beckers, Hannes Neuwirt, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 1, 2002
Effect of dialysis on serum/plasma levels of free immunoglobulin light chains in end-stage renal disease patientsGerald Cohen, Michael Rudnicki, Sabine Schmaldienst, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|October 31, 2012
SOCS-3 is downregulated in progressive CKD patients and regulates proliferation in human renal proximal tubule cells in a STAT1/3 independent mannerHannes Neuwirt, Iris E Eder, Martin Puhr, et al.
Experimental Cell Research|October 12, 2005
Overexpression of MyoD-inducible lysosomal sialidase (neu1) inhibits myogenesis in C2C12 cellsMarc J Champigny, Robert Perry, Michael Rudnicki, et al.
Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis|March 16, 2010
Risk factors for peritoneal dialysis-associated peritonitis: the role of oral active vitamin dMichael Rudnicki, Julia Kerschbaum, Johann Hausdorfer, et al.
Frontiers in Immunology|January 29, 2026
A rapid method to reduce drug interferences for antibody measurements in pegunigalsidase alfa-treated patients with Fabry diseaseMalte Lenders, Elisa Rudolph, Michael Rudnicki, et al.
Wiener Klinische Wochenschrift|March 29, 2011
Sevelamer use and incidence of peritonitis in peritoneal dialysisJulia Kerschbaum, Paul König, Johann Hausdorfer, et al.
Genes & Development|December 20, 2012
Genome-wide identification of enhancers in skeletal muscle: the role of MyoD1Roy Blum, Vasupradha Vethantham, Christopher Bowman, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 30, 2024
Relevance of Neutralizing Antibodies for the Pharmacokinetics of Pegunigalsidase Alfa in Patients with Fabry DiseaseMalte Lenders, Elise Raphaela Menke, Michael Rudnicki, et al.
Journal of the American Society of Nephrology : JASN|May 25, 2001
Glucose-modified proteins modulate essential functions and apoptosis of polymorphonuclear leukocytesGerald Cohen, Michael Rudnicki, Franziska Walter, et al.
Pageof 10

Showing results (11-20 of 93) with videos related to

Sort By:
Pageof 10
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|July 26, 2015
RNA expression signatures and posttranscriptional regulation in diabetic nephropathyMichael Rudnicki, Anneleen Beckers, Hannes Neuwirt, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 1, 2002
Effect of dialysis on serum/plasma levels of free immunoglobulin light chains in end-stage renal disease patientsGerald Cohen, Michael Rudnicki, Sabine Schmaldienst, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|October 31, 2012
SOCS-3 is downregulated in progressive CKD patients and regulates proliferation in human renal proximal tubule cells in a STAT1/3 independent mannerHannes Neuwirt, Iris E Eder, Martin Puhr, et al.
Experimental Cell Research|October 12, 2005
Overexpression of MyoD-inducible lysosomal sialidase (neu1) inhibits myogenesis in C2C12 cellsMarc J Champigny, Robert Perry, Michael Rudnicki, et al.
Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis|March 16, 2010
Risk factors for peritoneal dialysis-associated peritonitis: the role of oral active vitamin dMichael Rudnicki, Julia Kerschbaum, Johann Hausdorfer, et al.
Frontiers in Immunology|January 29, 2026
A rapid method to reduce drug interferences for antibody measurements in pegunigalsidase alfa-treated patients with Fabry diseaseMalte Lenders, Elisa Rudolph, Michael Rudnicki, et al.
Wiener Klinische Wochenschrift|March 29, 2011
Sevelamer use and incidence of peritonitis in peritoneal dialysisJulia Kerschbaum, Paul König, Johann Hausdorfer, et al.
Genes & Development|December 20, 2012
Genome-wide identification of enhancers in skeletal muscle: the role of MyoD1Roy Blum, Vasupradha Vethantham, Christopher Bowman, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 30, 2024
Relevance of Neutralizing Antibodies for the Pharmacokinetics of Pegunigalsidase Alfa in Patients with Fabry DiseaseMalte Lenders, Elise Raphaela Menke, Michael Rudnicki, et al.
Journal of the American Society of Nephrology : JASN|May 25, 2001
Glucose-modified proteins modulate essential functions and apoptosis of polymorphonuclear leukocytesGerald Cohen, Michael Rudnicki, Franziska Walter, et al.
Pageof 10